Pharma KOL Engagement: From Advisory Boards to Advocacy
How to stratify, sequence, and convert key opinion leaders from passive awareness to active advocacy — without crossing compliance lines.
Stratify by influence, not title
Use publication count, guideline involvement, peer-citation graphs, and digital reach. Combine into a single influence score and tier KOLs accordingly.
Sequence touchpoints over 18 months
Advisory board, scientific exchange, congress symposium, co-authored publication, registry investigator, speaker bureau. Each step earns the next.
Measure advocacy, not attendance
Track unprompted mentions in publications, guideline drafts, and peer-to-peer education. That is the real ROI signal.
Compliance as design constraint
Sunshine reporting, fair market value, and medical/commercial firewalls are guardrails. Design the program inside them from day one.
Ready to put this into practice?
We embed with HealthTech, pharma, and medical device commercial teams as growth partners — not consultants. Start with a 10-minute Trust Audit or book a discovery call.